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Purpose: To compare the effects of alendronate and
raloxifene on lumbar bone mineral density (BMD), bone
turnover, and lipid metabolism in elderly women with
osteoporosis. Subjects and Methods: One hundred twenty-
two postmenopausal women with osteoporosis (mean age:
69.4 years) were randomly divided into 2 groups of 61
patients: the alendronate group and the raloxifene group.
BMD of the lumbar spine, urinary level of cross-linked
N-terminal telopeptides of type I collagen (NTX), and serum
levels of alkaline phosphatase (ALP), total cholesterol (TC),
high and low density lipoprotein cholesterols (LDL-C and
HDL-C, respectively), and triglycerides (TG) were measured
during the 12-month-treatment period. Results: The trial in
50 patients in the alendronate group and 52 patients in the
raloxifene group could be completed. Both alendronate and
raloxifene increased lumbar BMD (+8.0% and +2.4% at 12
months, respectively), followed by reductions of urinary
NTX level and serum ALP level; however, the effects of
alendronate were more pronounced than those of raloxifene.
Only raloxifene reduced the serum levels of TC and LDL-C
(-3.9% and -7.7% at 12 months, respectively), without any
significant effect on the serum HDL-C and TG levels.
Conclusion: The present study confirmed the efficacy of
alendronate greater than raloxifene in increasing lumbar
BMD through its effect on marked reduction of the bone
turnover more than by raloxifene, and some beneficial
effects of raloxifene on lipid metabolism in elderly women
with osteoporosis.
Key Words: Alendronate, raloxifene, osteoporosis, postmeno-
pausal women, lipid metabolism
INTRODUCTION
Osteoporosis most commonly affects postmen-
opausal women, thus placing them at a significant
risk for fractures. Since fractures in the elderly
often lead to disability and increase the risk of
mortality,
1,2 appropriate and timely management
of osteoporosis is extremely important. Alendronate
(ALN) and raloxifene (RAL) have been widely
used in the treatment of osteoporosis in postmen-
opausal women because current evidence, which
is strictly based on the principles of evidence-
based medicine (EBM), suggests both the short-
term and long-term anti-fracture efficacy and safety
of ALN and RAL in postmenopausal women with
osteoporosis.
3-7
According to the results of randomized con-
trolled trials (RCTs) and meta-analyses of RCTs,
ALN and RAL effectively prevent vertebral frac-
tures in postmenopausal women with osteo-
porosis,
3,4,8-10 and ALN is also useful for the
prevention of nonvertebral and hip fractures.
3,4
However, because RAL has been shown to be
effective in preventing the initial vertebral fracture
in postmenopausal osteoporotic women without
prevalent vertebral fractures,
8 it is considered to
be the first-line drug in the treatment of younger
postmenopausal women with mild osteoporosis
or osteopenia with some risk factors for fractures,
whereas ALN is primarily considered to be the
first-line drug in the treatment of elderly women
with osteoporosis who have some risk factors for
falls. While no significant differences in the
efficacy in terms of the risk reduction of vertebral
Comparison of Effects of Alendronate and Raloxifene on
Lumbar Bone Mineral Density, Bone Turnover, and Lipid





1 and Hideo Matsumoto
1
1Department of Sports Medicine, Keio University School of Medicine, Tokyo;
2Department of Neurology, Mitate Hospital,
Fukuoka;
3Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan.
Received June 11, 2007
Accepted September 7, 2007
Reprint address: requests to Dr. Jun Iwamoto, Department of
Sports Medicine, Keio University School of Medicine, 35 Shinano-
machi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: 81-3-3353-1211,
Fax: 81-3-3352-9467, E-mail: jiwamoto@sc.itc.keio.ac.jpJun Iwamoto, et al.
Yonsei Med J Vol. 49, No. 1, 2008
fractures have been reported between ALN and
RAL, ALN is probably more efficacious than RAL
for the prevention of nonvertebral and hip
fractures. On the other hand, RAL has been
reported to reduce serum cholesterol level in
postmenopausal women with osteoporosis.
11
Although RCTs have demonstrated a similar
incidence of gastrointestinal adverse events in
postmenopausal osteoporotic women treated with
ALN and placebo,
9,10 gastrointestinal (GI) adverse
events are often encountered in practice during
ALN treatment, necessitating discontinuation of
the drug. One of the solutions in such cases is to
switch from ALN to RAL treatment. However, the
efficacy of RAL in elderly women with osteo-
porosis is not well established, and it remains
uncertain whether RAL is safe and effective for
reducing the bone turnover, increasing bone
mineral density (BMD), and preventing vertebral
fractures as ALN in elderly women with
osteoporosis. The purpose of this open-labeled
prospective study was to compare the effects of
ALN and RAL on lumbar BMD, bone turnover,
and lipid metabolism, as well as on the incidence
of vertebral fractures in elderly women with
osteoporosis. In particular, the primary end point
was lumbar BMD, and the secondary end point
was bone turnover markers.
SUBJECTS AND METHODS
Subjects
One hundred twenty-two postmenopausal
women (mean age: 69.4 years) were recruited at
Keiyu Orthopaedic Hospital (Gunma, Japan) in
September - December 2005. All of them were
diagnosed as having osteoporosis according to the
Japanese diagnostic criteria.
12,13 According to the
Japanese criteria for the diagnosis of osteoporosis
in women, patients with BMD < 70% of the young
adult mean (YAM), or of 70 - 80% of the YAM
along with a history of osteoporotic fractures, are
diagnosed as having osteoporosis. Patients were
randomly divided into 2 groups of 61 patients: the
ALN (5 mg daily) group and RAL (60 mg daily)
group. The doses indicated in the parentheses are
the doses mainly used in elderly Japanese women
with osteoporosis, since they have been recognized
to be safe and effective.
14-16 The duration of
treatment was 12 months. Preliminary screening
included medical history, physical examination,
plain X-rays of the thoracic and lumbar spine,
lumbar BMD measurement, and blood and
urinary biochemical tests. Subjects with a history
of reflux esophagitis, gastric or duodenal ulcers,
or gastrectomy were excluded. Current smokers,
and subjects treated with either glucocorticoid,
hyperthyroidism, or statins were also excluded.
Lumbar BMD was measured, and the assessment
of vertebral fractures on the plain X-ray film was
performed as described below. The serum levels
of calcium, phosphorus, alkaline phosphatase
(ALP), total cholesterol (TC), high and low density
lipoprotein cholesterols (LDL-C and HDL-C,
respectively), and triglycerides (TG) were measured
using standard laboratory techniques. The urinary
level of cross-linked N-terminal telopeptides of
type I collagen (NTX) was measured by enzyme-
linked immunosorbent assay. None of the subjects
suffered from any metabolic bone diseases, had a
history of hormone (estrogen) replacement
therapy, or had ever taken medication known to
affect bone metabolism prior to the present study.
All the subjects were instructed to consume about
800 mg of dietary calcium daily during the study
period. Informed consent was obtained from each
participant prior to participation in the study.
Table 1 illustrates the baseline characteristics of
the study subjects, and Table 2 illustrates the
serum levels of lipid metabolism markers at
baseline. There were no significant differences in
any of the baseline characteristics between the 2
groups (as determined by the unpaired t-test). The
mean serum levels of TC, TG, LDL-C and HDL-C
at baseline were all within the normal ranges.
After the start of the treatment, the urinary level
of NTX was measured at 3 months, lumbar BMD
and serum levels of calcium, phosphorus, ALP,
TC, LDL-C, HDL-C, and TG were measured every
6 months, and plain X-rays of the thoracic and
lumbar spine were assessed at the end of 12
months of treatment. We compared changes in
lumbar BMD, urinary NTX and serum ALP levels,
and components of the serum lipid profile
between the 2 groups. We also examined the
incidence of vertebral fractures. This protocol wasAlendronate and Raloxifene for Osteoporosis
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approved by the Ethics Committee of Keiyu
Orthopaedic Hospital.
Measurement of lumbar BMD
BMD of the lumbar spine (L1-L4) in the anter-
oposterior view was measured by dual-energy X-
ray absorptiometry (DXA) using a Hologic QDR
1500 W apparatus (Bedford, MA, USA). The
coefficient of variation (100 × standard deviation/
mean) of 5 measurements with repositioning
within 72 hours each time was less than 1.2% in
3 patients.
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and
lumbar spine were obtained to detect evidence of
vertebral fractures. According to the Japanese
criteria, a vertebral fracture is defined according
to the vertebral height on lateral X-ray films.
12,13
In brief, the vertebral height was measured at the
Table 1. Characteristics of Study Subjects
ALN (n = 61) RAL (n = 61)
Age (yrs) 70.3 ± 7.6 68.5 ± 7.2
Height (m) 1.48 ± 0.06 1.49 ± 0.06
Body weight (kg) 47.9 ± 6.8 48.4 ± 6.8
Body mass index (kg/m ) 21.9 ± 2.6 21.7 ± 2.5
Lumbar BMD (g/cm ) 0.620 ± 0.084 0.647 ± 0.070
%YAM of lumbar BMD (%) 61.4 ± 8.3 64.0 ± 6.9
Serum calcium (mg/dL) 9.4 ± 0.5 9.3 ± 0.4
Serum phosphorus (mg/dL) 3.3 ± 0.6 3.3 ± 0.6
Serum ALP (IU/L) 247 ± 92 249 ± 75
Urinary NTX (nM BCE/mM Cr) 69.3 ± 31.4 71.9 ± 27.2
Number of vertebral fractures 1.59 ± 1.93 1.30 ± 2.04
Percentage of patients with prevalent vertebral fracture 55.7 52.5
Percentage of patients with prevalent vertebral fracture.
Data are expressed as the mean ± SD.
ALN, alendronate group; RAL, raloxifene group; BMD, bone mineral density; YAM, young adult mean; ALP, alkaline
phosphatase; NTX, cross linked N-terminal telopeptides of type I collagen.
There were no significant differences in any characteristics between the 2 groups (by the unpaired t-test).
Table 2. Serum Lipid Metabolism Markers at Baseline
Normal range ALN (n = 61) RAL (n = 61)
Total cholesterol (mg/dL) 130 - 219 214 ± 34 209 ± 27
Triglycerides (mg/dL) 30 - 149 139 ± 68 127 ± 58
LDL-cholesterol (mg/dL) 70 - 139 125 ± 29 122 ± 27
HDL-cholesterol (mg/dL) 40 - 90 62 ± 16 61 ± 14
Data are expressed as the mean ± SD.
ALN, alendronate group; RAL, raloxifene group; LDL, low density lipoprotein; HDL, high density lipoprotein.
There were no significant differences in any parameters between the 2 groups (by the unpaired t-test).Jun Iwamoto, et al.
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anterior (A), central (C), and posterior (P) parts of
the vertebral body, and the presence of a vertebral
fracture was confirmed when (1) a reduction in
the vertebral height was more than 20% (A, C,
and P) compared to the height of the adjacent
vertebrae, (2) the C/A or C/P was less than 0.8,
or the (3) A/P was less than 0.75. The assessment
for vertebral fractures was performed at the T4-L4
level.
Statistical analysis
Data were expressed as mean ± standard devia-
tion (SD) in tables and as mean ± standard error
(SE) in figures. Data were compared between the
2 groups by unpaired t-test. The significance of
longitudinal changes in the parameters was deter-
mined by one-way analysis of variance (ANOVA)
with repeated measures. The incidence of vertebral
fractures was compared in the 2 groups by
Fisher’s exact test. All statistical analyses were
performed using the Stat View-J5.0 program on a
Windows computer. A significance level of p <
0.05 was used for all comparisons.
RESULTS
Adverse events
Eleven patients in the ALN group and 9
patients in the RAL group discontinued treatment
during the 12 month period. Table 3 shows the
reasons for the dropouts from the study. The main
reasons were epigastric pain, gastric ulcer, and
difficulty in compliance in the ALN group, and
epigastric pain and difficulty in compliance in the
RAL group. No serious adverse events that
necessitated hospitalization were observed in
either group. Thus, the trial could successfully be
completed in 50 (82.0%) patients in the ALN
group and 52 (85.2%) patients in the RAL group,
and the data from a total of 102 patients were
included in the analyses.
Changes in lumbar BMD, serum calcium and
phosphorus, and bone turnover markers
Fig. 1 and 2 show longitudinal changes in lumbar
BMD, serum levels of calcium and phosphorus,
and levels of the bone turnover markers. A
significant reduction in urinary NTX level was
observed in both groups (both p < 0.0001 by one-
way ANOVA with repeated measures). However,
there was a significant difference in the percent
decrease in the urinary NTX level between the 2
groups (44.6% in the ALN group and 34.5% in the
RAL group, p < 0.05 by the unpaired t-test).
Significant increases in lumbar BMD and signifi-
cant decreases in the serum calcium and ALP
levels were observed in both groups (p < 0.01, p <
0.001, and p < 0.0001, respectively, by one-way
ANOVA with repeated measures). There was a
significant difference in the percent decrease in
the serum ALP level at 6 months between the 2
groups (- 14.1% in the ALN group and - 5.0% in
the RAL group, p < 0.05 by the unpaired t-test).
There was also a significant difference in the
Table 3. Reasons for Drop Out of the Study
ALN (n = 11) RAL (n = 9)
Epigastric pain (n = 3) Epigastric pain (n = 4)
Difficulty in compliance (n = 3) Difficulty in compliance (n = 3)
Gastric ulcer (n = 1) Liver dysfunction (n = 1)
Heartburn (n = 1) Urticaria (n = 1)
Liver dysfunction (n = 1)
Diarrhea (n = 1)
Constipation (n = 1)
Eleven patients in the ALN (alendronate) group and 9 patients in the RAL (raloxifene) group dropped out of the study
because of the above reasons.
Namely, 82.0% and 85.2% of patients in the respective group completed the trial.Alendronate and Raloxifene for Osteoporosis
Yonsei Med J Vol. 49, No. 1, 2008
Fig. 1. Changes in urinary NTX. Data are expressed as the mean ± SE. One-way ANOVA with repeated measurements was
used to examine the significance of the longitudinal changes in the urinary NTX level. The unpaired t-test was used to
compare the percent changes in the urinary NTX level between the 2 groups. A significant reduction of the urinary NTX
level was observed in the both groups (both p < 0.0001 by the one-way ANOVA with repeated measurements). However,
there was a significant difference in the percent decrease in the urinary NTX level between the 2 groups (44.6% for the
ALN group and 34.5% for the RAL group, p < 0.05 by the unpaired t-test). *p < 0.05 vs. RAL. ALN, alendronate (n = 50);
RAL, raloxifene (n = 52); NTX, cross linked N-terminal telopeptides of type I collagen.
Fig. 2. Percent changes in serum biochemical markers and lumbar BMD. Data are expressed as the mean ± SE. One-way
ANOVA with repeated measurements was used to examine the significance of the longitudinal changes in biochemical
markers and the lumbar BMD. A significant increase in the lumbar BMD and significant decreases in the serum calcium
and ALP levels were observed in the both groups (p < 0.01, p < 0.001, and p < 0.0001, respectively, by the one-way ANOVA
with repeated measurements). There was a significant difference in the percent decrease in the serum ALP level at 6 months
between the 2 groups (-14.1% for the ALN group and -5.0% for the RAL group, p < 0.05 by the unpaired t-test). There also
was a significant difference in the percent increase in the lumbar BMD at 12 months between the 2 groups (+8.0% for the
ALN group and +2.4% for the RAL group, p < 0.01 by the unpaired t-test). *p < 0.05 vs. RAL, **p < 0.01 vs. RAL. ALN,
alendronate (n = 50); RAL, raloxifene (n = 52); BMD, bone mineral density; ALP, alkaline phosphatase.Jun Iwamoto, et al.
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percent increase in the lumbar BMD at 12 months
between the 2 groups (+8.0% in the ALN group
and +2.4% in the RAL group, p < 0.01 by the
unpaired t-test).
Changes in the components of the serum lipid
profile
Fig. 3 shows longitudinal changes in the serum
TC, LDL-C, HDL-C, and TG levels in the 2 groups.
Significant decreases in the serum TC and LDL-C
levels were observed in the RAL group (p < 0.01
and p < 0.001, respectively, by one-way ANOVA
with repeated measures). However, no significant
changes in any of the components of the serum
lipid profile were observed in the ALN group (by
one-way ANOVA with repeated measures). There
was a significant difference in the percent
decrease in the serum LDL-C level at 12 months
between the 2 groups (+0.4% in the ALN group
and - 7.7% in the RAL group, p < 0.05 by the
unpaired t-test). The percent decrease in the
serum TC level at 12 months, relative to the
baseline in the RAL group was 3.9%.
Incidence of vertebral fractures
After 12 months of treatment, the incidence of
vertebral fractures was 14.0% in the ALN group
and 13.1% in the RAL group, whereas no signifi-
cant difference in the incidence of vertebral
fractures was observed between the 2 groups.
DISCUSSION
The present study showed that treatment with
both ALN and RAL increased lumbar BMD
(+8.0% and +2.4% at 12 months, respectively),
followed by reductions of the urinary NTX level
Fig. 3. Percent changes in serum lipid metabolism markers. Data are expressed as the mean ± SE. One-way ANOVA with
repeated measurements was used to examine the significance of the longitudinal changes in the serum lipid metabolism
markers. Significant decreases in the serum TC and LDL-C levels were observed in the RAL groups (p < 0.01 and p < 0.001,
respectively, by the one-way ANOVA with repeated measurements). However, no significant changes in any serum lipid
markers were observed in the ALN group (by the one-way ANOVA with repeated measurements). There was a significant
difference in the percent decrease in the serum LDL-C level at 12 months between the 2 groups (+0.4% for the ALN group
and -7.7% for the RAL group, p < 0.05 by the unpaired t-test). *p < 0.05 vs. ALN. ALN, alendronate (n = 50); RAL, raloxifene
(n = 52); TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein.Alendronate and Raloxifene for Osteoporosis
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(- 44.6% and - 34.5% at 3 months, respectively)
and serum ALP level (- 17.7% and - 9.6% at 12
months, respectively). However, the effects of
ALN were more pronounced than those of RAL.
Only RAL reduced the serum TC and LDL-C
levels (- 3.9% and -7.7% at 12 months, respectively).
Thus, we confirmed the greater efficacy of ALN
than RAL in increasing lumbar BMD through its
effect to reduce the bone turnover more markedly
than by RAL and some beneficial effects of RAL
on the lipid metabolism in elderly women with
osteoporosis. However, the incidence of vertebral
fractures was similar in the 2 groups (14.0% in the
ALN group and 13.1% in the RAL group).
According to previous reports on the effects of
ALN and RAL on lumbar BMD and bone turnover
markers in Japanese postmenopausal women with
osteoporosis (mean ages: 63 - 65 years), ALN
decreases the urinary deoxypyridinoline level by
about 38% at 3 months and increases lumbar BMD
by 6.21% at 1 year,
14 while RAL decreases the
urinary NTX level by about 26% at 3 months and
increases lumbar BMD by 3.5% at 1 year.
16
Previously, the Efficacy of Fosamax versus Evista
Comparison Trial (EFFECT), conducted to compare
the effects of ALN and RAL on BMD in post-
menopausal women with low BMD (mean age, 62
years), revealed that the improvements in BMD
and markers of bone turnover were substantially
greater during treatment with ALN than with
RAL.
17 Thus, the effects of ALN on lumbar BMD
and bone turnover in younger postmenopausal
women with osteoporosis appear to be more
pronounced than those of RAL. However, a direct
comparison of the efficacy of ALN and RAL in
elderly women with osteoporosis in a single study
has rarely been reported. The effects of ALN and
RAL on lumbar BMD in the present study (mean
age: 69.4 years) appear to be consistent with
previous results (mean ages: 63 - 66 years).
14-16
The difference in the efficacy of the 2 drugs in
increasing lumbar BMD might be attributed to the
greater efficacy of ALN in reducing bone turnover
than that of RAL. The greater the suppression of
bone turnover, the greater the increase in lumbar
BMD.
18-21 The bisphosphonates inhibit osteoclast-
mediated bone resorption, and loss of osteoclast
function and apoptosis is the consequence of loss
of function of one or more important signaling
proteins. In particular, nitrogen-containing bis-
phosphonates like ALN are not metabolized, but
can inhibit enzymes of the mevalonate pathway,
thereby preventing the biosynthesis of isoprenoid
compounds, which are essential for post-transla-
tional modification of small GTPases.
22 On the
other hand, RAL is a nonsteroidal benzothiophene
that binds to estrogen receptors and inhibits bone
resorption without stimulating the uterine endo-
metrium in postmenopausal women.
11 Thus, the
mechanism of inhibition of bone resorption and,
consequently, the degree of anti-resorptive effect
may differ between ALN and RAL. In the present
study, the RAL group showed less pronounced
reductions in bone turnover markers than the
ALN group, consistent with previous results.
Additional studies showed that the incidence of
vertebral fractures during a 1-year treatment
period with ALN in Japanese postmenopausal
women with osteoporosis (mean age: 71 - 73 years)
is 2% to 3%,
15 and that the incidence during a
1-year treatment period with RAL in Asian
postmenopausal women with osteoporosis (mean
age: 64 - 66 years) is 0%.
23 Recently, the Evista
ALN comparison (EVA) trial was conducted to
compare the anti-fracture efficacy of ALN and
RAL; however, this study could not be completed
because of inability to collect a sufficient number
of study subjects.
24 Based on the prevalence of
vertebral fractures at baseline, our subjects might
have had more severe osteoporosis than those in
previous studies, and the incidence of vertebral
fractures was higher in the present study than
that reported in previous studies.
15,23 Despite the
difference in the efficacy on lumbar BMD, the
anti-fracture efficacy in our subjects against
vertebral fractures was similar in ALN and RAL,
although the present study might not have suf-
ficient power to allow a conclusion on the drugs’
effect on vertebral fractures.
It has recently been established that the anti-
fracture efficacy of anti-resorptive drugs cannot be
explained simply by alterations of BMD, and that
there is in fact, overall improvement of the bone
quality in postmenopausal women with osteo-
porosis, when treated with these drugs.
25,26 Bone
strength reflects both bone mass and bone quality,
and bone quality is derived from bone architec-
ture, turnover, damage accumulation, mineraliza-Jun Iwamoto, et al.
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tion, and matrix.
27 Clinically, the effects of the
above mentioned drugs on bone quality have not
yet been clearly established. However, the
incidence of fractures could be considered as an
index of bone quality, because reduction of the
fracture risk is considered to be the most con-
vincing evidence of the improved bone quality. In
particular, the reduction of the levels of bone
turnover markers to their respective normal
ranges has been reported to be important for
reducing the incidence of vertebral and non-
vertebral fractures in postmenopausal women
with osteoporosis.
25,26 In the present study, both
ALN and RAL reduced the urinary NTX level to
the normal range for Japanese women (9.3 - 54.3
nmol BCE/mmol Cr),
28 and the incidence of
vertebral fractures was similar in the 2 groups.
The increase of lumbar BMD was smaller in the
RAL group than in the ALN group, suggesting
that RAL might have a more significant effect on
bone quality than on BMD.
Eleven patients (18.0%) in the ALN group
dropped out of the study, and the main reasons
for the dropouts were gastric problems and
difficulty in compliance. GI adverse symptoms are
considered to be the most significant adverse
effects of ALN even though RCTs have reported
no statistically significant difference in the in-
cidence of GI adverse events between postmeno-
pausal women with osteoporosis treated with
ALN and placebo.
9,10 Cryer and Bauer
29 have
argued that upper GI adverse events reported
during treatment with bisphosphonates may
reflect high background incidence of upper GI
complaints, and that RCTs, which represent the
highest level of evidence, suggest little or no
increase in the risk of upper GI problems with
bisphosphonates, provided that they were admini-
stered properly. It has been suggested that
increased sensitivity to detect upper GI symptoms
in elderly women with osteoporosis is more likely
than the existence of a causal relationship between
upper GI symptoms and ALN.
On the other hand, 9 patients (14.8%) in the
RAL group dropped out of the study, and the
main reasons for the dropouts were also gastric
problems and difficulty in compliance. The main
adverse effects of RAL reported from the Multiple
Outcomes of RAL Evaluation (MORE) study
include hot flashes, leg cramps, and deep vein
thrombosis (DVT).
8 However, it was shown in 1
study conducted, on Asian postmenopausal women
with osteoporosis that the incidence of these
complications did not differ significantly between
the RAL and placebo groups.
30 It is likely that
race, that is, Caucasian or Asian, may influence
the incidence of DVT. Adverse events like gastric
problems have rarely been reported. However, in
the present study, the above mentioned adverse
events were not observed while GI problems were
frequently observed. Thus, attention should be
paid to such adverse events during the treatment
with RAL. It has been reported that the risk of
invasive breast cancer is reduced in postmen-
opausal women with osteoporosis when treated
with RAL,
31 which could be important for
pharmacoeconomy and long-term adherence to
treatment. Thus, providing such information to
patients might lead to improvement of adherence
with RAL treatment.
It is known that RAL reduces serum levels of
TC, LDL-C, and TG in postmenopausal women
with osteoporosis.
11 In Japanese postmenopausal
women with osteoporosis, RAL has been reported
to decrease serum levels of TC and LDL-C by
about 7% and 11%, respectively.
16 In the present
study also, serum levels of TC and LDL-C in the
RAL group decreased (3.9% and 7.7%, respec-
tively). Because serum TG level can strongly be
affected by food intake, no significant change in
this parameter was probably observed after RAL
treatment. The degree of reduction of serum TC
and LDL-C levels was quite small, therefore, it
remains uncertain if such small reductions help
prevent coronary heart disease (CHD) in these
patients. One study reported that while RAL
reduced the incidence of clinical vertebral fractures,
it did not significantly affect the risk of CHD in
postmenopausal women with CHD or multiple
risk factors for CHD.
32 Thus, the benefits of RAL
treatment in reducing vertebral fractures should
carefully be weighed against the increased risk of
DVT and fatal stroke associated with the
administration of this drug.
32 Further studies are
needed to confirm the beneficial effects of RAL in
the prevention of CHD in Japanese postmenopausal
women with osteoporosis and CHD or risk factors
for CHD.Alendronate and Raloxifene for Osteoporosis
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There are some notable limitations of this study.
First, the study was not a double-blind trial but
an open-labeled study. Therefore, some of the
results might be biased. Second, the number of
study subjects was relatively small and not large
enough to lend sufficient power to the results.
Double-blind randomized placebo-controlled studies
conducted on a sufficient number of subjects are
needed to confirm the present results. Third,
despite the fact that serum levels of calcium and
phosphorus could be affected by seasonal variations
of vitamin D, serum levels of 25-hydroxyvitamin
D were not assessed in the present study. Thus,
further studies are needed to clarify the influence
of ALN or RAL treatment as well as seasonal
variations of vitamin D on calcium and phosphorus
metabolism.
In conclusion, the present head-to-head trial
showed that treatment of elderly women with
osteoporosis with both ALN and RAL increased
lumbar BMD followed by reduction of bone
turnover; however, the effects of ALN were more
pronounced than those of RAL, and only RAL
reduced serum levels of TC and LDL-C. Thus,
ALN increased lumbar BMD with greater efficacy
than RAL in elderly women with osteoporosis
through marked reduction of bone turnover. On
the other hand, RAL appeared to have some
beneficial effects on lipid metabolism in subjects.
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